Cargando…

Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Correction Notice
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949816/ https://www.ncbi.nlm.nih.gov/pubmed/36844188 http://dx.doi.org/10.1097/HS9.0000000000000856

Ejemplares similares

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
por: Sonneveld, Pieter, et al.
Publicado: (2022)

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P. G., et al.
Publicado: (2018)

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
por: Siegel, David S., et al.
Publicado: (2020)

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
por: Dimopoulos, M A, et al.
Publicado: (2017)

Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis
por: Onda, Yoshiyuki, et al.
Publicado: (2022)

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P G, et al.
Publicado: (2017)

Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure
por: Siegel, David S., et al.
Publicado: (2019)

Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma
por: Mele, Giuseppe, et al.
Publicado: (2018)

Retrospective Study of Carfilzomib-Pomalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients in a Tertiary Care Hospital in India
por: Mehta, Pallavi, et al.
Publicado: (2021)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study
por: Biran, Noa, et al.
Publicado: (2019)

New drugs in multiple myeloma – role of carfilzomib and pomalidomide
por: Jurczyszyn, Artur, et al.
Publicado: (2014)

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
por: Sivaraj, Dharshan, et al.
Publicado: (2018)

Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)
por: Kalff, Anna, et al.
Publicado: (2021)

Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma
por: Derman, Benjamin A., et al.
Publicado: (2023)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network
por: Antonioli, Elisabetta, et al.
Publicado: (2023)

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
por: Gasparetto, Cristina, et al.
Publicado: (2021)

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
por: Fotiou, Despina, et al.
Publicado: (2022)

Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial
por: Dimopoulos, Meletios A., et al.
Publicado: (2022)

Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study
por: Astarita, Anna, et al.
Publicado: (2023)

Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma
por: Abe, Yu, et al.
Publicado: (2023)

Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd)
por: Byun, Ja Min, et al.
Publicado: (2020)

Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel
por: Leleu, Xavier, et al.
Publicado: (2022)

P901: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN LENALIDOMIDE–PRETREATED MULTIPLE MYELOMA: A SUBANALYSIS OF OPTIMISMM BY FRAILTY
por: Oriol, A., et al.
Publicado: (2022)

Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma
por: Matsue, Kosei, et al.
Publicado: (2015)

Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2023)

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

P48 CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE REAL-LIFE EXPERIENCE OF THE REGIONAL TUSCAN MYELOMA NETWORK (RTM)
por: Attucci, I., et al.
Publicado: (2023)

Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan
por: Suzuki, Kenshi, et al.
Publicado: (2017)

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
por: Dimopoulos, Meletios, et al.
Publicado: (2020)

Correction Notice: Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
Publicado: (2021)

Pomalidomide‐bortezomib‐dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM
por: Sunami, Kazutaka, et al.
Publicado: (2020)

Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
por: Büyükkaramikli, Nasuh C., et al.
Publicado: (2017)

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
por: Dimopoulos, Meletios A., et al.
Publicado: (2018)

Case of Stroke from Cerebral Vasculitis following Carfilzomib, Lenalidomide, and Dexamethasone Therapy in a Patient with Relapsing Multiple Myeloma
por: Osafehinti, Deborah, et al.
Publicado: (2019)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
por: Richardson, Paul G., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bj0f5f70h0lnkde0amddaj8dn4